Literature DB >> 21665310

Epithelial-mesenchymal-transition induced by EGFR activation interferes with cell migration and response to irradiation and cetuximab in head and neck cancer cells.

Carmen Holz1, Franziska Niehr, Mariya Boyko, Tsvetana Hristozova, Luitpold Distel, Volker Budach, Ingeborg Tinhofer.   

Abstract

BACKGROUND AND
PURPOSE: The role of epithelial-mesenchymal transition (EMT) in the poor outcome of EGFR-overexpressing SCCHN was evaluated.
MATERIAL AND METHODS: SCCHN cell lines were characterized for their cell morphology and expression of EGFR and the EMT-associated factors E-cadherin, vimentin and Snail1. The migratory potential of cells was assessed in motility assays. Response to irradiation and cetuximab was determined using clonogenic survival assays.
RESULTS: High basal expression of E-cadherin but low to absent vimentin expression could be observed in all SCCHN cell lines. Although E-cadherin expression levels did not change after treatment with EGF we observed a significant change in cell morphology resembling EMT. SCCHN cells with high basal levels of Snail1 resulting from constitutive EGFR activation were characterized by mesenchymal-like morphology, elevated migratory potential, reduced sensitivity to irradiation and cetuximab but increased sensitivity to the combined treatment.
CONCLUSIONS: Autocrine activation of EGFR leading to EMT is associated with a metastatic phenotype and reduced sensitivity of SCCHN cells to single-modality treatment with cetuximab or irradiation. The potential of Snail1 as biomarker for selection of patients who will mostly benefit from a combination of cetuximab and radiotherapy has to be evaluated in future clinical studies. Copyright Â
© 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21665310     DOI: 10.1016/j.radonc.2011.05.042

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  39 in total

1.  Relationship between CD44high/CD133high/CD117high cancer stem cells phenotype and Cetuximab and Paclitaxel treatment response in head and neck cancer cell lines.

Authors:  Ana Livia Silva Galbiatti-Dias; Glaucia Maria Mendonça Fernandes; Marcia Maria Urbanin Castanhole-Nunes; Luiza Fernandes Hidalgo; Carlos Henrique Viesi Nascimento Filho; Rosa Sayoko Kawasaki-Oyama; Leticia Antunes Muniz Ferreira; Patricia Matos Biselli-Chicote; Érika Cristina Pavarino; Eny Maria Goloni-Bertollo
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

Review 2.  The quest to overcome resistance to EGFR-targeted therapies in cancer.

Authors:  Curtis R Chong; Pasi A Jänne
Journal:  Nat Med       Date:  2013-11-07       Impact factor: 53.440

3.  Evaluation of EGFR as a prognostic and diagnostic marker for head and neck squamous cell carcinoma patients.

Authors:  Hana Polanska; Martina Raudenska; Kristyna Hudcová; Jaromir Gumulec; Marketa Svobodova; Zbynek Heger; Michaela Fojtu; Hana Binkova; Zuzana Horakova; Rom Kostrica; Vojtech Adam; Rene Kizek; Michal Masarik
Journal:  Oncol Lett       Date:  2016-07-21       Impact factor: 2.967

Review 4.  Reversion of the ErbB malignant phenotype and the DNA damage response.

Authors:  E Aaron Runkle; Hongtao Zhang; Zheng Cai; Zhiqiang Zhu; Barry L Karger; Shiaw-Lin Wu; Donald M O'Rourke; Zhaocai Zhou; Qiang Wang; Mark I Greene
Journal:  Exp Mol Pathol       Date:  2012-09-27       Impact factor: 3.362

5.  Molecular profiles of cancer stem-like cell populations in aggressive thyroid cancers.

Authors:  Mariavittoria Dima; Valeria Pecce; Mauro Biffoni; Cira Rosaria Tiziana Di Gioia; Giovanni Tallini; Marco Biffoni; Francesca Rosignolo; Antonella Verrienti; Marialuisa Sponziello; Giuseppe Damante; Diego Russo; Cosimo Durante
Journal:  Endocrine       Date:  2015-09-14       Impact factor: 3.633

6.  Effect of epithelial growth factor on matrix metalloproteinase-2 and E-cadherin/β-catenin expression in an in situ model of tumorigenesis.

Authors:  Natalia Festugatto Navarini; Vera Cavalcanti De Araújo; Marcelo Sperandio; Marcelo Henrique Napimoga; Lucas Novaes Teixeira; Ney Soares De Araújo; Elizabeth Ferreira Martinez
Journal:  Oncol Lett       Date:  2017-06-30       Impact factor: 2.967

Review 7.  Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance.

Authors:  Carolien Boeckx; Marc Baay; An Wouters; Pol Specenier; Jan B Vermorken; Marc Peeters; Filip Lardon
Journal:  Oncologist       Date:  2013-07-02

Review 8.  Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma.

Authors:  Ana Markovic; Christine H Chung
Journal:  Expert Rev Anticancer Ther       Date:  2012-09       Impact factor: 4.512

9.  IL4 and IL-17A provide a Th2/Th17-polarized inflammatory milieu in favor of TGF-β1 to induce bronchial epithelial-mesenchymal transition (EMT).

Authors:  Xiaoying Ji; Jinxiu Li; Li Xu; Wenjing Wang; Ming Luo; Shuangling Luo; Libing Ma; Keng Li; Subo Gong; Long He; Zhijun Zhang; Ping Yang; Zhiguang Zhou; Xudong Xiang; Cong-Yi Wang
Journal:  Int J Clin Exp Pathol       Date:  2013-07-15

Review 10.  A comparison of epithelial-to-mesenchymal transition and re-epithelialization.

Authors:  Philip L Leopold; Jan Vincent; Hongjun Wang
Journal:  Semin Cancer Biol       Date:  2012-07-31       Impact factor: 15.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.